logo

Kalvista Pharmaceuticals, Inc. (KALV)



Trade KALV now with
  Date
  Headline
4/22/2019 7:38:43 AM KalVista Pharma Appoints Daniel Soland To Board
3/27/2019 7:32:00 AM KalVista Pharma Announces Promotion Of Benjamin Palleiko To Chief Business Officer
3/14/2019 7:36:31 AM KalVista Q3 Loss Per Share $0.23 Vs Loss $0.49 Last Year
2/1/2019 7:32:23 AM KalVista Pharma Appoints Brian Pereira To Board Of Directors
1/4/2019 7:33:27 AM KalVista : – KVD900 Phase 2 HAE Trial Data Expected In 2019
12/14/2018 7:31:52 AM KalVista Pharma Q2 Net Loss $3.3 Mln Or $0.22/Shr Vs Loss $5.0 Mln Or $0.50/Shr Last Year
11/12/2018 7:30:56 AM KalVista Pharma Provides Clinical Update On KVD900
9/14/2018 7:31:48 AM KalVista Q1 Loss Per Share $0.47 Vs Loss $0.51 Last Year
9/6/2018 9:15:49 AM KalVista Prices Public Offering Of 4 Mln Common Shares At $17.00 Per Share
9/5/2018 4:03:46 PM KalVista Pharmaceuticals Announces Proposed Public Offering Of Common Stock
7/31/2018 7:17:17 AM KalVista Pharma Q4 Net Loss $0.7 Mln Or $0.06/Shr Vs Loss $4.2 Mln Or $0.43/Shr Last Year
5/29/2018 7:33:15 AM KalVista Pharmaceuticals : KVD900 Data Accepted For Late Breaking Poster Session
3/16/2018 7:34:38 AM KalVista Q3 Loss Per Share $0.49 Vs Loss $1.03 Last Year
1/5/2018 7:34:23 AM KalVista Pharma Commences Two Clinical Trials